Last reviewed · How we verify
FSME-Immune vaccination
FSME-Immune vaccination is a Inactivated viral vaccine Biologic drug developed by Medical University of Vienna. It is currently FDA-approved for Prevention of tick-borne encephalitis (TBEV infection).
FSME-Immune is an inactivated tick-borne encephalitis virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against TBEV.
FSME-Immune is an inactivated tick-borne encephalitis virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against TBEV. Used for Prevention of tick-borne encephalitis (TBEV infection).
At a glance
| Generic name | FSME-Immune vaccination |
|---|---|
| Sponsor | Medical University of Vienna |
| Drug class | Inactivated viral vaccine |
| Target | Tick-borne encephalitis virus (TBEV) envelope proteins |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated TBEV antigen that triggers both humoral (antibody) and cell-mediated immune responses. This priming of the adaptive immune system enables rapid recognition and neutralization of the virus upon natural exposure, preventing infection or reducing disease severity.
Approved indications
- Prevention of tick-borne encephalitis (TBEV infection)
Common side effects
- Injection site pain, redness, or swelling
- Headache
- Myalgia
- Fatigue
- Low-grade fever
Key clinical trials
- Primary TBE Vaccination for the Elderly (PHASE4)
- Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun® (PHASE4)
- Influence of Persistent CMV-infection on Immune Senescence (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FSME-Immune vaccination CI brief — competitive landscape report
- FSME-Immune vaccination updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI
Frequently asked questions about FSME-Immune vaccination
What is FSME-Immune vaccination?
How does FSME-Immune vaccination work?
What is FSME-Immune vaccination used for?
Who makes FSME-Immune vaccination?
What drug class is FSME-Immune vaccination in?
What development phase is FSME-Immune vaccination in?
What are the side effects of FSME-Immune vaccination?
What does FSME-Immune vaccination target?
Related
- Drug class: All Inactivated viral vaccine drugs
- Target: All drugs targeting Tick-borne encephalitis virus (TBEV) envelope proteins
- Manufacturer: Medical University of Vienna — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of tick-borne encephalitis (TBEV infection)
- Compare: FSME-Immune vaccination vs similar drugs
- Pricing: FSME-Immune vaccination cost, discount & access